Clinical Trial Update: AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 first-in-human study of AMG 176 in relapsed or refractory multiple myeloma and acute myeloid leukemia was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Multiple Myeloma

Drugs mentioned

• AMG 176

Snippet

Sponsor: Amgen | Conditions: Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | Status: TERMINATED | Results posted: 2025-07-09